File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Fat-derived hormone adiponectin combined with FTY720 significantly improves small-for-size fatty liver graft survival

TitleFat-derived hormone adiponectin combined with FTY720 significantly improves small-for-size fatty liver graft survival
Authors
KeywordsAnti-steatosis
Cell survival signaling
Hepatic microcirculation
Liver transplantation
Marginal graft
Issue Date2006
PublisherBlackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/AJT
Citation
American Journal Of Transplantation, 2006, v. 6 n. 3, p. 467-476 How to Cite?
AbstractOwing to the discrepancy between organ donation and the demand for liver transplantation, expanding the liver donor pool is of vital importance. However, marginal liver grafts, such as small-for-size and/or fatty grafts, were associated with primary graft nonfunction or poor function. Therefore, novel combination therapies to rescue small-for-size fatty liver grafts should be investigated. In this study, we applied a combination therapy using a fat-derived hormone adiponectin (anti-steatosis) plus immunomodulator FTY720 (anti-inflammatory) in a rat liver transplantation model using small-for-size fatty liver grafts, and investigated the underlying protective mechanism such as anti-steatosis, intra-graft energy metabolism, hepatic microcirculatory changes, cell signaling cascades for survival, apoptosis and inflammation. The current study demonstrated that even a single treatment of adiponectin or FTY720 improved the 7-day graft survival from 0% to 62.5% (p = 0.001). The combination therapy significantly increased the 7-day graft survival rate to 100% by remarkable attenuation of graft steatosis and acute phase inflammatory response, significant activation of cell survival Akt pathway and maintenance of intra-graft adenosine triphosphate metabolism and improvement of hepatic microcirculation. In conclusion, the fat-derived hormone adiponectin combined with FTY720 might be a novel combination drug therapy for prevention of small-for-size fatty liver graft injury. © 2006 The American Society of Transplantation and the American Society of Transplant Surgeons.
Persistent Identifierhttp://hdl.handle.net/10722/78451
ISSN
2014 Impact Factor: 5.683
2014 SCImago Journal Rankings: 2.514
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorMan, Ken_HK
dc.contributor.authorZhao, Yen_HK
dc.contributor.authorXu, Aen_HK
dc.contributor.authorLo, CMen_HK
dc.contributor.authorLam, KSLen_HK
dc.contributor.authorNg, KTen_HK
dc.contributor.authorHo, JWYen_HK
dc.contributor.authorSun, CKen_HK
dc.contributor.authorLee, TKen_HK
dc.contributor.authorLi, XLen_HK
dc.contributor.authorFan, STen_HK
dc.date.accessioned2010-09-06T07:43:02Z-
dc.date.available2010-09-06T07:43:02Z-
dc.date.issued2006en_HK
dc.identifier.citationAmerican Journal Of Transplantation, 2006, v. 6 n. 3, p. 467-476en_HK
dc.identifier.issn1600-6135en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78451-
dc.description.abstractOwing to the discrepancy between organ donation and the demand for liver transplantation, expanding the liver donor pool is of vital importance. However, marginal liver grafts, such as small-for-size and/or fatty grafts, were associated with primary graft nonfunction or poor function. Therefore, novel combination therapies to rescue small-for-size fatty liver grafts should be investigated. In this study, we applied a combination therapy using a fat-derived hormone adiponectin (anti-steatosis) plus immunomodulator FTY720 (anti-inflammatory) in a rat liver transplantation model using small-for-size fatty liver grafts, and investigated the underlying protective mechanism such as anti-steatosis, intra-graft energy metabolism, hepatic microcirculatory changes, cell signaling cascades for survival, apoptosis and inflammation. The current study demonstrated that even a single treatment of adiponectin or FTY720 improved the 7-day graft survival from 0% to 62.5% (p = 0.001). The combination therapy significantly increased the 7-day graft survival rate to 100% by remarkable attenuation of graft steatosis and acute phase inflammatory response, significant activation of cell survival Akt pathway and maintenance of intra-graft adenosine triphosphate metabolism and improvement of hepatic microcirculation. In conclusion, the fat-derived hormone adiponectin combined with FTY720 might be a novel combination drug therapy for prevention of small-for-size fatty liver graft injury. © 2006 The American Society of Transplantation and the American Society of Transplant Surgeons.en_HK
dc.languageengen_HK
dc.publisherBlackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/AJTen_HK
dc.relation.ispartofAmerican Journal of Transplantationen_HK
dc.rightsThe definitive version is available at www.blackwell-synergy.com-
dc.subjectAnti-steatosisen_HK
dc.subjectCell survival signalingen_HK
dc.subjectHepatic microcirculationen_HK
dc.subjectLiver transplantationen_HK
dc.subjectMarginal graften_HK
dc.subject.meshFatty Liver - pathology - surgery-
dc.subject.meshGraft Rejection - blood - drug therapy - pathology-
dc.subject.meshGraft Survival - drug effects-
dc.subject.meshImmunosuppressive Agents - therapeutic use-
dc.subject.meshLiver Transplantation-
dc.titleFat-derived hormone adiponectin combined with FTY720 significantly improves small-for-size fatty liver graft survivalen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1600-6135&volume=6&issue=3&spage=467&epage=476&date=2006&atitle=Fat-derived+hormone+adiponectin+combined+with+FTY720+significantly+improves+small-for-size+fatty+liver+graft+survivalen_HK
dc.identifier.emailMan, K: kwanman@hku.hken_HK
dc.identifier.emailXu, A: amxu@hkucc.hku.hken_HK
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_HK
dc.identifier.emailLam, KSL: ksllam@hku.hken_HK
dc.identifier.emailNg, KT: ledodes@hku.hken_HK
dc.identifier.emailLee, TK: tkwlee@hkucc.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.authorityMan, K=rp00417en_HK
dc.identifier.authorityXu, A=rp00485en_HK
dc.identifier.authorityLo, CM=rp00412en_HK
dc.identifier.authorityLam, KSL=rp00343en_HK
dc.identifier.authorityNg, KT=rp01720en_HK
dc.identifier.authorityLee, TK=rp00447en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1600-6143.2005.01201.xen_HK
dc.identifier.pmid16468955-
dc.identifier.scopuseid_2-s2.0-33644885246en_HK
dc.identifier.hkuros116888-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33644885246&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume6en_HK
dc.identifier.issue3en_HK
dc.identifier.spage467en_HK
dc.identifier.epage476en_HK
dc.identifier.isiWOS:000235224200005-
dc.publisher.placeDenmarken_HK
dc.identifier.scopusauthoridMan, K=7101754072en_HK
dc.identifier.scopusauthoridZhao, Y=7407402718en_HK
dc.identifier.scopusauthoridXu, A=7202655409en_HK
dc.identifier.scopusauthoridLo, CM=7401771672en_HK
dc.identifier.scopusauthoridLam, KSL=8082870600en_HK
dc.identifier.scopusauthoridNg, KT=7403178513en_HK
dc.identifier.scopusauthoridHo, JWY=7402649982en_HK
dc.identifier.scopusauthoridSun, CK=7404248685en_HK
dc.identifier.scopusauthoridLee, TK=7501439435en_HK
dc.identifier.scopusauthoridLi, XL=13008588500en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK
dc.identifier.citeulike503077-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats